Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation
Open Access
- 16 November 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (3), 208-218
- https://doi.org/10.1093/eurheartj/ehac632
Abstract
Biomarkers specifically related to atrial tissue may increase the understanding of the pathophysiology of atrial fibrillation (AF) and further improve risk prediction in this setting. Bone morphogenetic protein 10 (BMP10) is a protein expressed in the atrial myocardium. We evaluated the association between BMP10 and the risk of ischaemic stroke and other cardiovascular events in large cohorts of patients with AF, treated with and without oral anticoagulation (OAC). BMP10 was measured in plasma samples collected at randomisation in patients with AF without OAC in the ACTIVE A and AVERROES trials (n = 2974), and with OAC in the ARISTOTLE trial (n = 13 079). BMP10 was analysed with a prototype Elecsys immunoassay. Associations with outcomes were evaluated by Cox-regression models adjusted for clinical characteristics, kidney function, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Median concentrations of BMP10 were 2.47 and 2.44 ng/mL, in the non-OAC and OAC cohort, respectively. Increasing BMP10 was associated with lower body mass index, older age, female sex, kidney dysfunction, and AF rhythm. BMP10 was consistently associated with ischaemic stroke. In the non-OAC cohort, BMP10 increased the concordance index of the multivariable model from 0.713 to 0.733 (P = 0.004) and in the OAC cohort from 0.673 to 0.694 (P < 0.001). Additionally, BMP10 maintained a significant prognostic value after additionally adjusting for NT-proBNP. BMP10 was not independently associated with bleeding or with death. The novel atrial biomarker BMP10 was independently associated with ischaemic stroke in patients with AF irrespective of OAC treatment. BMP10 seems to be more specifically related to the risk of ischaemic stroke in AF. In this study, BMP10 may be a novel specific biomarker of ischaemic stroke in patients with atrial fibrillation, irrespective of oral anticoagulation.Keywords
Funding Information
- Sanofi
- Bristol Myers Squibb (BMS) Co.
- Population Health Research Institute
- Duke Clinical Research Institute
- Uppsala Clinical Research Center
- Roche Diagnostics International
- Swedish Society for Medical Research
- Hjärt-Lungfonden
- Swedish Heart Lung Foundation
- Uppsala University Hospital
This publication has 28 references indexed in Scilit:
- N-Terminal Pro–B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation)Journal of the American College of Cardiology, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- PITX2c Is Expressed in the Adult Left Atrium, and Reducing Pitx2c Expression Promotes Atrial Fibrillation Inducibility and Complex Changes in Gene ExpressionCirculation: Cardiovascular Genetics, 2011
- Apixaban in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- The Association of the 4q25 Susceptibility Variant for Atrial Fibrillation With Stroke Is Limited to Stroke of Cardioembolic EtiologyStroke, 2010
- Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleAmerican Heart Journal, 2010
- Chromosome 4q25 Variants and Atrial Fibrillation Recurrence After Catheter AblationJournal of the American College of Cardiology, 2010
- Effect of Clopidogrel Added to Aspirin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- B-Type Natriuretic Peptide (BNP) and N-Terminal Pro-BNP in Obese Patients without Heart Failure: Relationship to Body Mass Index and Gastric Bypass SurgeryClinical Chemistry, 2006
- Impact of Obesity on Plasma Natriuretic Peptide LevelsCirculation, 2004